Anders Gaardsdal Holst

Anders Gaardsdal Holst

Auto-generated profile, based on publicly available information

Anders Gaardsdal Holst

Novo Nordisk A/S, Søborg, Denmark

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
AAAndrew J. Ahmann
Andrew J. Ahmann
MCMatthew Capehorn
Matthew Capehorn
GCGuillaume Charpentier
Guillaume Charpentier
FDFrancesco Dotta
Francesco Dotta
EHElena Henkel
Elena Henkel
VAVanita R. Aroda
Vanita R. Aroda
OBJECTIVE To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA1c at week 56. RESULTS Mean HbA1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] –0.62% [95% CI –0.80, –0.44] [–6.78 mmol/mol (95% CI –8.70, –4.86)]; P < 0.0001 for noninferiority and superiority). Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD –3.78 kg [95% CI –4.58, –2.98]; P < 0.0001). Significantly more subjects treated with semaglutide (67%) achieved HbA1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%). Both treatments had similar safety profiles, but gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER–treated subjects (33.3%); injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%). CONCLUSIONS Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.

2 December 2010 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
BWBo Gregers Winkel
Bo Gregers Winkel
AHAnders Gaarsdal Holst
Anders Gaarsdal Holst
JTJuliane Theilade
Juliane Theilade
IKIngrid Bayer Kristensen
Ingrid Bayer Kristensen
JTJørgen Lange Thomsen
Jørgen Lange Thomsen
JTJacob Tfelt-Hansen
Jacob Tfelt-Hansen
Aims The aim of this investigation was to study the incidence of sudden cardiac death (SCD) in persons aged 1–35 years in a nationwide setting (5.38 million people) by systematic evaluation of all deaths. Methods and results All deaths in persons aged 1–35 years in Denmark in 2000–06 were included. Death certificates were read independently by two physicians. The National Patient Registry was used to retrieve information on prior medical history. All autopsy reports were read and the cause of death was revised based on autopsy findings. We identified 625 cases of sudden unexpected death (10% of all deaths), of which 156 (25%) were not autopsied. Of the 469 autopsied cases, 314 (67%) were SCD. The most common cardiac cause of death was ischaemic heart disease (13%); 29% of autopsied sudden unexpected death cases were unexplained. In 45% of SCD cases, the death was witnessed; 34% died during sleep; 89% were out-of-hospital deaths. Highest possible incidence rate of SCD in the young was 2.8 per 100 000 person-years including non-autopsied cases of sudden unexpected death. Excluding those, the incidence rate declined to 1.9 per 100 000 person-years. Conclusions A total of 7% of all deaths in the young can be attributed to SCD, when including non-autopsied cases (autopsy ratio 75%). The incidence rate of SCD in the young of 2.8 per 100 000 person-years is higher than previously reported.

4 May 2010 in Circulation
Verified
Journal Article
Closed access
PDF file
AHAnders G. Holst
Anders G. Holst
GJGorm Jensen
Gorm Jensen
EPEva Prescott
Eva Prescott
Background— Studies have suggested a link between risk factors for atherosclerotic disease and venous thromboembolism (VTE), but results are heterogeneous. We sought to identify risk factors for VTE with a focus on risk factors for atherosclerotic disease. Methods and Results— Data were taken from the Copenhagen City Heart Study, a prospective cohort study of a random, age-stratified sample of people living in a defined area in Copenhagen, Denmark, started in 1976 with follow-up until 2007. First VTE (deep vein thrombosis and pulmonary embolism) diagnosis was retrieved from electronic national registries from study baseline to 2007. Of 18 954 subjects (median follow-up, 19.5 years) representing 360 399 person-years of follow-up, 969 subjects experienced at least 1 VTE, corresponding to a crude incidence rate of 2.69 (95% confidence interval [CI], 2.52 to 2.86) per 1000 person-years. The variables found to be significantly associated with VTE in a multivariable model adjusted for age and calendar time were as follows: body mass index (hazard ratio [HR] for ≥35 versus 100 versus <80 mm Hg=1.34 [95% CI, 1.08 to 1.66]). Other cardiovascular risk factors including total/high-density lipoprotein/low-density lipoprotein cholesterol levels, triglyceride levels, and diabetes mellitus were not associated with VTE. Conclusions— Obesity and smoking were both found to be important risk factors for VTE whereas total/high-density lipoprotein/low-density lipoprotein cholesterol levels, triglyceride levels, and diabetes mellitus were not.

16 October 2014 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
JSJørg Saberniak
Jørg Saberniak
NHNina E. Hasselberg
Nina E. Hasselberg
RBRasmus Borgquist
Rasmus Borgquist
PPPyotr G Platonov
Pyotr G Platonov
SSSebastian I. Sarvari
Sebastian I. Sarvari
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
Aims Exercise increases risk of ventricular arrhythmia in subjects with arrhythmogenic right ventricular cardiomyopathy (ARVC). We aimed to investigate the impact of exercise on myocardial function in ARVC subjects. Methods and Results We included 110 subjects (age 42 ± 17 years), 65 ARVC patients and 45 mutation‐positive family members. Athletes were defined as subjects with ≥4 h vigorous exercise/week [≥1440 metabolic equivalents (METs × minutes/week)] during a minimum of 6 years. Athlete definition was fulfilled in 37/110 (34%) subjects. We assessed right ventricular (RV) and left ventricular (LV) myocardial function by echocardiography, and by magnetic resonance imaging (MRI). The RV function by RV fractional area change (FAC), RV global longitudinal strain (GLS) by echocardiography, and RV ejection fraction (EF) by MRI was reduced in athletes compared with non‐athletes (FAC 34 ± 9% vs. 40 ± 11%, RVGLS –18.3 ± 6.1% vs. –22.0 ± 4.8%, RVEF 32 ± 8% vs. 43 ± 10%, all P < 0.01). LV function by LVEF and LVGLS was reduced in athletes compared with non‐athletes (LVEF by echocardiography 50 ± 10% vs. 57 ± 5%, LVEF by MRI 46 ± 6% vs. 53 ± 8%, and LVGLS –16.7 ± 4.2% vs. –19.4 ± 2.9%, all P < 0.01). The METs × minutes/week correlated with reduced RV and LV function by echocardiography and MRI (all P < 0.01). The LVEF by MRI was also reduced in subgroups of athlete index patients (46 ± 7% vs. 54 ± 10%, P = 0.02) and in athlete family members (47 ± 3% vs. 52 ± 6%, P < 0.05). Conclusion Athletes showed reduced biventricular function compared with non‐athletes in ARVC patients and in mutation‐positive family members. The amount and intensity of exercise activity was associated with impaired LV and RV function. Exercise may aggravate and accelerate myocardial dysfunction in ARVC.

4 September 2012 in European Heart Journal
Verified
Journal Article
Open access
PDF file
BBBarbara E. Bussink
Barbara E. Bussink
AHAnders G. Holst
Anders G. Holst
LJLasse Jespersen
Lasse Jespersen
JDJaap W. Deckers
Jaap W. Deckers
GJGorm B. Jensen
Gorm B. Jensen
EPEva Prescott
Eva Prescott
To determine the prevalence, predictors of newly acquired, and the prognostic value of right bundle branch block (RBBB) and incomplete RBBB (IRBBB) on a resting 12-lead electrocardiogram in men and women from the general population. We followed 18 441 participants included in the Copenhagen City Heart Study examined in 1976–2003 free from previous myocardial infarction (MI), chronic heart failure, and left bundle branch block through registry linkage until 2009 for all-cause mortality and cardiovascular outcomes. The prevalence of RBBB/IRBBB was higher in men (1.4%/4.7% in men vs. 0.5%/2.3% in women, P < 0.001). Significant predictors of newly acquired RBBB were male gender, increasing age, high systolic blood pressure, and presence of IRBBB, whereas predictors of newly acquired IRBBB were male gender, increasing age, and low BMI. Right bundle branch block was associated with significantly increased all-cause and cardiovascular mortality in both genders with age-adjusted hazard ratios (HR) of 1.31 [95% confidence interval (CI), 1.11–1.54] and 1.87 (95% CI, 1.48–2.36) in the gender pooled analysis with little attenuation after multiple adjustment. Right bundle branch block was associated with increased risk of MI with an HR of 1.67 (95% CI, 1.16–2.42) and pacemaker insertion with an HR of 2.17 (95% CI, 1.22–3.86), but not with chronic heart failure (HR 1.37; 95% CI, 0.96–1.94), atrial fibrillation (HR 1.10; 95% CI, 0.73–1.67), or chronic obstructive pulmonary disease (HR 0.99; 95% CI, 0.60–1.62). The presence of IRBBB was not associated with any adverse outcome. In this cohort study, RBBB and IRBBB were two to three times more common among men than women. Right bundle branch block was associated with increased cardiovascular risk and all-cause mortality, whereas IRBBB was not. Contrary to common perception, RBBB in asymptomatic individuals should alert clinicians to cardiovascular risk.

1 October 2010 in Heart Rhythm
Verified
Journal Article
Closed access
AHAnders Gaarsdal Holst
Anders Gaarsdal Holst
BWBo Gregers Winkel
Bo Gregers Winkel
JTJuliane Theilade
Juliane Theilade
IKIngrid Bayer Kristensen
Ingrid Bayer Kristensen
JTJørgen Lange Thomsen
Jørgen Lange Thomsen
JTJacob Tfelt-Hansen
Jacob Tfelt-Hansen